Drug Profile
Research programme: adenosine A3-receptor antagonists - King Pharmaceuticals
Latest Information Update: 26 Feb 2008
Price :
$50
*
At a glance
- Originator University of Ferrara
- Developer King Pharmaceuticals Research and Development
- Class
- Mechanism of Action Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Sep 2005 This programme is still in active development
- 26 Nov 2002 This programme is still in active development
- 27 Mar 2000 Medco Research has been acquired by King Pharmaceuticals